Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED APRIL 2012. Refer to TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (which replaced NICE TA251) for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | dasatinib (Sprycel®) | |
| Formulation | film-coated tablet | |
| Reference number | 878 | |
| Indication | Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia in the chronic phase |
|
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Full | |
| Status | Superseded | |
| Advice number | 1211 | |
| NMG meeting date | 20/07/2011 | |
| AWMSG meeting date | 14/09/2011 | |
| Ratification by Welsh Government | 17/01/2012 | |
| Date of issue | 19/01/2012 | |
| NICE guidance | TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
|